FDA hits ALX Oncology with partial clinical hold, capping PhII studies at 50 patients while safety check ensues
ALX Oncology $ALXO has been hit with a partial clinical hold.
The Burlingame, CA-based biotech announced the news Monday morning saying their Phase II studies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
